09/693,558

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAY 01	New CAS web site launched
NEWS 3	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 4	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 5	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 6	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 7	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 8	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 9	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 10	JUN 29	STN Viewer now available
NEWS 11	JUN 29	STN Express, Version 8.2, now available
NEWS 12	JUL 02	LEMBASE coverage updated
NEWS 13	JUL 02	LMEDLINE coverage updated
NEWS 14	JUL 02	SCISEARCH enhanced with complete author names
NEWS 15	JUL 02	CHEMCATS accession numbers revised
NEWS 16	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 17	JUL 16	CAplus enhanced with French and German abstracts
NEWS 18	JUL 18	CA/CAplus patent coverage enhanced
NEWS 19	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 20	JUL 30	USGENE now available on STN
NEWS 21	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 22	AUG 06	BEILSTEIN updated with new compounds
NEWS 23	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 24	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 25	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:17:55 ON 21 AUG 2007

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:18:06 ON 21 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 AUG 2007 HIGHEST RN 945102-95-4
DICTIONARY FILE UPDATES: 20 AUG 2007 HIGHEST RN 945102-95-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\09693558_genus.str



chain nodes :
7 8 9 10 17
ring nodes :
1 2 3 4 5 6 11 12 13 14 15 16
chain bonds :
4-7 7-8 8-9 8-10 9-17 11-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-16 11-12 12-13 13-14 14-15 15-16
exact/norm bonds :
8-9 8-10 9-17 11-16 11-12 12-13 13-14 14-15 15-16
exact bonds :
4-7 7-8 11-17
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 12:18:24 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 9313 TO ITERATE

100.0% PROCESSED 9313 ITERATIONS 180 ANSWERS
SEARCH TIME: 00.00.01

L2 180 SEA SSS FUL L1

=> d scan

L2 180 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Propenamide, N-[4-[1-(diphenylmethyl)-4-piperidinyl]butyl]-3-(1-oxido-3-pyridinyl)-, (E)- (9CI)
MF C30 H35 N3 O2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 180 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 3-Pyridinepentanamide, N-[4-(4-piperidinyl)butyl]- (9CI)
MF C19 H31 N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file medlie caplus wpids uspatfull
'MEDLIE' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):medline
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	172.31

FILE 'MEDLINE' ENTERED AT 12:18:58 ON 21 AUG 2007

FILE 'CAPLUS' ENTERED AT 12:18:58 ON 21 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 12:18:58 ON 21 AUG 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 12:18:58 ON 21 AUG 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l2
SAMPLE SEARCH INITIATED 12:19:11 FILE 'WPIDS'
SAMPLE SCREEN SEARCH COMPLETED - 51 TO ITERATE

100.0% PROCESSED 51 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 296 TO 724
PROJECTED ANSWERS: 3 TO 81

L3 47 L2

=> s l3 not py>2003
L4 12 L3 NOT PY>2003

=> d l4 1-12 ibib, abs

L4 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:185435 CAPLUS
DOCUMENT NUMBER: 141:218446
TITLE: Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma
AUTHOR(S): Drevs, Joachim; Loeser, Roland; Rattel, Benno; Esser, Norbert
CORPORATE SOURCE: Department of Medical Oncology, Tumor Biology Center, Germany
SOURCE: Anticancer Research (2003), 23(6C), 4853-4858
CODEN: ANTRD4; ISSN: 0250-7005
PUBLISHER: International Institute of Anticancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB FK 866/ K 22.175 (FK-866), developed as an anticancer agent, interferes with the NAD+ biosynthesis and therefore might have characteristics distinct from conventional chemotherapeutic agents. We investigated FK-866 in a murine renal cell carcinoma model (RENCA) to assess its antitumor, antimetastatic and antiangiogenic potency. FK-866 was administered twice daily on days 10 to 15 after intrarenal inoculation of RENCA cells in syngenic Balb/c mice at oral doses of 6, 10, 14 and 18 mg/kg to define the optimal dose related to toxicity. For efficacy studies, FK-866 was administered orally twice daily at doses of 6 and 10 mg/kg or twice daily at doses of 3 and 5 mg/kg on days 14 to 19 after tumor cell inoculation. Animals in the pos. control group received 30 mg/kg TNP 470 s.c. on every other day beginning on day 1. On day 17, all animals were examined for blood flow in the left renal artery by color Doppler imaging (CDI). The animals were sacrificed on day 21 and analyzed for primary tumor weight and volume, number of metastases to the lung and abdominal lymph nodes and vessel d. in tumor tissues. Doses of up to 6 mg/kg FK-866 were less toxic than treatment with TNP-470. Significant antitumor efficacy was observed for doses of ≥10 mg/kg FK-866 only. In contrast, a significant decrease of vessel d. in tumor tissues by up to 70% could be detected for all dose groups. Changes in blood flow in the tumor feeding renal artery could not be detected because of the profound strong tumor reduction FK-866 has antitumoral and antimetastatic activity in RENCA mice. Furthermore, this is the first report to describe a strong antiangiogenic potency of FK-866.
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:885670 CAPLUS
DOCUMENT NUMBER: 140:174633
TITLE: FK866, a Highly Specific Noncompetitive Inhibitor of Nicotinamide Phosphoribosyltransferase, Represents a Novel Mechanism for Induction of Tumor Cell Apoptosis
AUTHOR(S): Hasmann, Max; Schemainda, Isabel
CORPORATE SOURCE: Fujisawa GmbH, Munich, 81673, Germany
SOURCE: Cancer Research (2003), 63(21), 7436-7442
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Deregulation of apoptosis, the physiol. form of cell death, is closely associated with immunol. diseases and cancer. Apoptosis is activated either by death receptor-driven or mitochondrial pathways, both of which may provide potential targets for novel anticancer drugs. Although several ligands stimulating death receptors have been described, the actual mol. events triggering the mitochondrial pathway are largely unknown. Here, we show initiation of apoptosis by gradual depletion of the intracellular coenzyme NAD+. We identified the first low mol. weight compound, designated

FK866, which induces apoptosis by highly specific, noncompetitive inhibition of nicotinamide phosphoribosyltransferase (NAPRT), a key enzyme in the regulation of NAD+ biosynthesis from the natural precursor nicotinamide. Interference with this enzyme does not primarily intoxicate cells because the mitochondrial respiratory activity and the NAD+-dependent redox reactions involved remain unaffected as long as NAD+ is not effectively depleted by catabolic reactions. Certain tissues, however, have a high turnover of NAD+ through its cleavage by enzymes like poly(ADP-ribose) polymerase. Such cells often rely on the more readily available nicotinamide pathway for NAD+ synthesis and undergo apoptosis after inhibition of NAPRT, whereas cells effectively using the nicotinic acid pathway for NAD+ synthesis remain unaffected. In support of this concept, FK866 effectively induced delayed cell death by apoptosis in HepG2 human liver carcinoma cells with an IC50 of .apprx.1 nM, did not directly inhibit mitochondrial respiratory activity, but caused gradual NAD+ depletion through specific inhibition of NAPRT. This enzyme, when partially purified from K562 human leukemia cells, was noncompetitively inhibited by FK866, and the inhibitor consts. were calculated to be 0.4 nM for the enzyme/substrate complex (Ki) and 0.3 nM for the free enzyme (Ki'), resp. Nicotinic acid and nicotinamide were both found to have antidote potential for the cellular effects of FK866. FK866 may be used for treatment of diseases implicating deregulated apoptosis such as cancer for immunosuppression or as a sensitizer for genotoxic agents. Furthermore, it may provide an important tool for investigation of the mol. triggers of the mitochondrial pathway leading to apoptosis through enabling temporal separation of NAD+ decrease from ATP breakdown and apoptosis by several days.

REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:485869 CAPLUS
DOCUMENT NUMBER: 139:261547
TITLE: A four component coupling strategy for the synthesis of D-phenylglycinamide-derived non-covalent factor Xa inhibitors
AUTHOR(S): Sheehan, Scott M.; Masters, John J.; Wiley, Michael R.; Young, Stephen C.; Liebeschuetz, John W.; Jones, Stuart D.; Murray, Christopher W.; Franciskovich, Jeffrey B.; Engel, David B.; Weber, Wayne W.; Marimuthu, Jothirajah; Kyle, Jeffrey A.; Smallwood, Jeffrey K.; Farmen, Mark W.; Smith, Gerald F.
CORPORATE SOURCE: Lilly Research Laboratories, A Division of Eli Lilly and Company, Indianapolis, IN, 46285, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(14), 2255-2259
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:261547
GI



I

AB A novel isonitrile derivative I (Boc = tert-butoxycarbonyl) was synthesized and used in an Ugi four component coupling reaction for the synthesis of D-phenylglycinamide derivs. as reversible factor Xa inhibitors. The aryl group substitution effects on inhibition of the coagulation cascade serine protease factor Xa was evaluated.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:706352 CAPLUS
DOCUMENT NUMBER: 133:276324
TITLE: Inhibitors of cellular nicotinamide mononucleotide formation, therapeutic use thereof,and identification and metabolic methods
INVENTOR(S): Biedermann, Elfi; Eisenburger, Rolf; Hasmann, Max; Loser, Roland; Rattel, Benno; Reiter, Friedemann; Schein, Barbara; Schemainda, Isabel; Schulz, Michael; Seibel, Klaus; Vogt, Klaus; Wosikowski, Katja
PATENT ASSIGNEE(S): Klinge Pharma G.m.b.H., Germany
SOURCE: Ger. Offen., 20 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19908483	A1	20001005	DE 1999-19908483	19990226
PRIORITY APPLN. INFO.:			DE 1999-19908483	19990226

AB Biol. active substances are described which inhibit the cellular formation of NMN, an essential intermediate in NAD(P) biosynthesis in the cell. These substances can be used for a pharmaceutical composition for the treatment of cancer, leukemia, or for Immunosuppression. Addnl., methods are described for the identification of such substances and for the investigation of a given cell type for its dependence on nicotinamide as a precursor in NAD synthesis.
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1990:158058 CAPLUS
DOCUMENT NUMBER: 112:158058
TITLE: Preparation of N-(1-benzyl-4-piperidinyl)alkyl derivatives of (hetero)arylcarboxamides as cholinesterase antagonists
INVENTOR(S): Goto, Giichi; Nagaoka, Akinobu
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: Eur. Pat. Appl., 19 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 330026	A1	19890830	EP 1989-102376	19890211
EP 330026	B1	19941005		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 02138255	A	19900528	JP 1989-26260	19890203
US 5169856	A	19921208	US 1989-306579	19890206
CA 1339895	C	19980602	CA 1989-590959	19890214
PRIORITY APPLN. INFO.:			JP 1988-32339 A	19880215
			JP 1988-114169 A	19880511

OTHER SOURCE(S): MARPAT 112:158058
GI For diagram(s), see printed CA Issue.
AB The title compds. [I; A = (un)substituted aryl; R1-R3 = H, (un)substituted C1-11 alkyl, C2-4 alkenyl, C2-4 alkynyl, Ph, naphthyl, cycloalkyl, bicyclooctyl, tricyclodecyl, etc.; n = 2-6] and their salts were prepared as

cholinesterase inhibitors, e.g., by a coupling reaction of arylcarboxylic acids II [Z = (activated) OH; A, R1 as above] with 4-piperidinylalkylamines III (R2 = H, R3 as above), followed by N-alkylation or -acylation. I are said to be useful for the prophylaxis and therapy of senile dementia, Alzheimer's disease, Huntington's chorea, etc. Et3N (1.0) mL was added to an ice-cooled solution of 1.05 g (E)-cinnamic acid and 1.8 g 4-(2-aminoethyl)-1-benzylpiperidine dihydrochloride in 20 mL DMF, followed by 1.7 g (EtO)2P(O)CN and the mixture was stirred and cooled 1 h to give intermediate I (A = Ph, R1 = R2 = H, R3 = PhCH2, n = 2) which was converted to its hydrochloride (IV). The latter (0.5 g) was stirred 6 h at 80° with 2.5 mL Ac2O in the presence of catalytic amount of tosic acid hydrate, treated with 10% NaOH and acidified with HCl to give I.HCl (R2 = Ac, other groups unchanged), which in vitro inhibited acetylcholinesterase activity with an IC50 of 0.64 μM, compared to 0.22 μM found for physostigmine. Tablets were prepared from IV 1, lactose 197, corn starch 50, and Mg stearate 2 g.

L4 ANSWER 6 OF 12 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN

L4 ANSWER 7 OF 12 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN

L4 ANSWER 8 OF 12 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN

L4 ANSWER 9 OF 12 USPATFULL on STN

ACCESSION NUMBER: 2002:288098 USPATFULL

TITLE: Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy

INVENTOR(S): Biedermann, Elfi, Vaterstetten, GERMANY, FEDERAL REPUBLIC OF
Eisenburger, Rolf, Kirchseeon, GERMANY, FEDERAL REPUBLIC OF
Hasmann, Max, Neuried, GERMANY, FEDERAL REPUBLIC OF
Loser, Roland, Feldafing, GERMANY, FEDERAL REPUBLIC OF
Rattel, Benno, Munich, GERMANY, FEDERAL REPUBLIC OF
Reiter, Friedemann, Putzbrunn, GERMANY, FEDERAL REPUBLIC OF
Schein, Barbara, Neufahrn, GERMANY, FEDERAL REPUBLIC OF
Schemainda, Isabel, Munich, GERMANY, FEDERAL REPUBLIC OF
Schulz, Michael, Aschheim, GERMANY, FEDERAL REPUBLIC OF
Seibel, Klaus, Grafelfing, GERMANY, FEDERAL REPUBLIC OF
Vogt, Klaus, Munich, GERMANY, FEDERAL REPUBLIC OF
Wosikowski, Katja, Poing, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Klinge Pharma GmbH (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002160968	A1	20021031
	US 6506572	B2	20030114
APPLICATION INFO.:	US 2001-935772	A1	20010823 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2000-EP1628, filed on 28 Feb 2000, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1999-103814	19990226

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FITCH EVEN TABIN AND FLANNERY, 120 SOUTH LA SALLE STREET, SUITE 1600, CHICAGO, IL, 60603-3406
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 28 Drawing Page(s)
LINE COUNT: 3127
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB New biologically active compounds are described which inhibit the cellular formation of niacinamide mononucleotide, and essential intermediate of the NAD(P) biosynthesis in the cell. These compounds can represent the active ingredient of a pharmaceutical composition for the treatment of cancers, leukaemias or for immunosuppression. Furthermore, screening methods are described as a tool for detecting the above active compounds, and for examination of a given cell type for its dependency on niacinamide as a precursor for NAD synthesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2002:239033 USPATFULL
TITLE: Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
INVENTOR(S): Biedermann, Elfi, Vaterstetten, GERMANY, FEDERAL REPUBLIC OF
Hasmann, Max, Neuried, GERMANY, FEDERAL REPUBLIC OF
Loser, Roland, Feldafing, GERMANY, FEDERAL REPUBLIC OF
Rattel, Benno, Munich, GERMANY, FEDERAL REPUBLIC OF
Reiter, Friedemann, Putzbrunn, GERMANY, FEDERAL REPUBLIC OF
Schein, Barbara, Neufahrn, GERMANY, FEDERAL REPUBLIC OF
Seibel, Klaus, Grafelfing, GERMANY, FEDERAL REPUBLIC OF
Vogt, Klaus, Munich, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Klinge Pharma GmbH, Munich, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6451816	B1	20020917
APPLICATION INFO.:	US 1998-216482		19981218 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1997-EP3244, filed on 20 Jun 1997
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Rotman, Alan L.
ASSISTANT EXAMINER: Desai, Rita
LEGAL REPRESENTATIVE: Fitch, Even, Tabin, & Flannery
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 4285
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the use of pharmacologically valuable pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides according to general formula (I) in the treatment of tumors or for immunosuppression. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2002:224728 USPATFULL
TITLE: Pyridyl alkane acid amides as cytostatics and immunosuppressives
INVENTOR(S): Biedermann, Elfi, Vaterstetten, GERMANY, FEDERAL REPUBLIC OF
Hasmann, Max, Neuried, GERMANY, FEDERAL REPUBLIC OF
Loser, Roland, Feldafing, GERMANY, FEDERAL REPUBLIC OF
Rattel, Benno, Munich, GERMANY, FEDERAL REPUBLIC OF
Reiter, Friedemann, Putzbrunn, GERMANY, FEDERAL REPUBLIC OF
Schein, Barbara, Neufahrn, GERMANY, FEDERAL REPUBLIC OF
Seibel, Klaus, Gra felfing, GERMANY, FEDERAL REPUBLIC

OF
Vogt, Klaus, Munich, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Klinge Pharma GmbH, Munich, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6444823	B1	20020903
APPLICATION INFO.:	US 1998-216075		19981218 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1997-EP3243, filed on 20 Jun 1997

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19624704	19960620

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Rotman, Alan L.
ASSISTANT EXAMINER: Desai, Rita
LEGAL REPRESENTATIVE: Fitch, Even, Tabin & Flannery
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3772
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to new pyridyl alkane acid amides according to general formula (I) as well as methods for their production, medicaments containing these compounds as well as their medical use, especially in the treatment of tumors or for immunosuppression. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 12 USPATFULL on STN
ACCESSION NUMBER: 92:101011 USPATFULL
TITLE: Piperidinoalkyl derivatives of carboxylic acid amides
INVENTOR(S): Goto, Giichi, Osaka, Japan
Nagaoka, Akinobu, Hyogo, Japan
PATENT ASSIGNEE(S): Takeda Chemical Industries, Inc., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5169856		19921208
APPLICATION INFO.:	US 1989-306579		19890206 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1988-32339	19880215
	JP 1988-114169	19880511

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Raymond, Richard L.
ASSISTANT EXAMINER: O'Sullivan, Peter G.
LEGAL REPRESENTATIVE: Wegner, Cantor, Mueller & Player
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 999
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to unsaturated carboxylic acid amide derivatives of the formula ##STR1## wherein ring A stands for an optionally substituted aromatic ring; R.sup.1 stands for a hydrogen atom or an optionally substituted hydrocarbon residue or forms an optionally substituted carbocyclic ring with the adjacent group --CH.dbd.C-- together with two carbon atoms constituting the ring A; R.sup.2 stands for a hydrogen atom, an optionally substituted hydrocarbon residue or an

optionally substituted acyl group; R.sup.3 stands for an optionally substituted hydrocarbon residue; and n denotes an integer ranging from 2 to 6, and salts thereof, as well as the production thereof.

The compounds of the present invention act on the central nervous system of mammals and has a strong anti-cholinesterase activity, which can be used for the prophylaxis and therapy of, for example, senile dementia, Alzheimer's diseases, Huntington's chorea, et., and are useful as medicines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:17:55 ON 21 AUG 2007)

FILE 'REGISTRY' ENTERED AT 12:18:06 ON 21 AUG 2007
L1 STRUCTURE UPLOADED
L2 180 S L1 FULL

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 12:18:58 ON 21 AUG 2007
L3 47 S L2
L4 12 S L3 NOT PY>2003

=> s l3 and "vitamin PP"
L5 1 L3 AND "VITAMIN PP"

=> d l5 ibib, abs

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:690954 CAPLUS
DOCUMENT NUMBER: 131:307106
TITLE: Use of vitamin PP compounds as cytoprotective agents in chemotherapy
INVENTOR(S): Biedermann, Elfi; Hasmann, Max; Loser, Roland; Rattel, Benno; Reiter, Friedemann; Schein, Barbara; Schemainda, Isabel; Seibel, Klaus; Vogt, Klaus; Wosikowski, Katja
PATENT ASSIGNEE(S): Klinge Pharma GmbH, Germany
SOURCE: PCT Int. Appl., 145 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9953920	A1	19991028	WO 1999-EP2686	19990421
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19818044	A1	19991028	DE 1998-19818044	19980422
EP 1031564	A1	20000830	EP 1999-103814	19990226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 9939282	A	19991108	AU 1999-39282	19990421
EP 1079832	A1	20010307	EP 1999-922119	19990421

```
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI
     JP 2002512190          T     20020423    JP 2000-544324          19990421
     AT 311186              T     20051215    AT 1999-922119          19990421
     ES 2253890             T3    20060601    ES 1999-922119          19990421
     WO 2000050399          A1    20000831    WO 2000-EP1628          20000228
        W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
            CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
            IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
            MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
            SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
            DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
            CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     EP 1154998             A1    20011121    EP 2000-907642          20000228
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO
     JP 2002537380          T     20021105    JP 2000-600982          20000228
     EP 1816124             A2    20070808    EP 2007-10337           20000228
        R:  AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,
            NL, PT, SE
     US 2002160968          A1    20021031    US 2001-935772          20010823
     US 6506572             B2    20030114
PRIORITY APPLN. INFO.:                       DE 1998-19818044    A   19980422
                                             EP 1999-103814      A   19990226
                                             WO 1999-EP2686      W   19990421
                                             EP 2000-907642      A3  20000228
                                             WO 2000-EP1628      W   20000228

OTHER SOURCE(S):         MARPAT 131:307106
AB   The invention relates to the use of vitamin PP compds.
     and/or compds. with anti-pellagra activity such as for example nicotinic
     acid (niacin), and nicotinamide (niacin-amide, vitamin
     PP, vitamin B3) for the reduction, elimination or prevention of
     side-effects of different degrees as well as for neutralization of acute
     side-effects in immunosuppressive or cancerostatic chemotherapy or
     diagnosis, especially with substituted pyridine carboxamides, as well as
     combination medicaments with an amount of compds. with vitamin B3 and/or
     anti-pellagra activity and chemotherapeutic agents are especially considered in
     the mentioned chemotherapies and indications.  Nicotinamide at 500 mg/kg
     twice daily protected mice treated i.p. with antitumor
     N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide.
     There were no deaths in the nicotinamide-treated mice and the strong reduction
     of leukocytes was completely prevented.
REFERENCE COUNT:         3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d his

     (FILE 'HOME' ENTERED AT 12:17:55 ON 21 AUG 2007)

     FILE 'REGISTRY' ENTERED AT 12:18:06 ON 21 AUG 2007
L1              STRUCTURE UPLOADED
L2          180 S L1 FULL

     FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 12:18:58 ON 21 AUG
     2007
L3           47 S L2
L4           12 S L3 NOT PY>2003
L5            1 S L3 AND "VITAMIN PP"

=> s l3 and "nicotinamide"
L6           18 L3 AND "NICOTINAMIDE"

=> d l6 1-18 ibib, abs
```

L6 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:561728 CAPLUS
DOCUMENT NUMBER: 147:9919
TITLE: Preparation of [1,3]thiazolo[5,4-b]pyridine-2-amine derivatives as VEGF receptor 2 kinase inhibitors
INVENTOR(S): Yoon, Seung-Hyun; Joo, Hyun Woo; Song, Jeong Uk; Kim, Young Kwan; Koo, Sun-Young; Yang, So Yeun; Kim, Kyoung-Hee; Hwang, Jin-a; Cho, Heung Soo; Choi, Hwan Geun; Lim, Dongchul; Song, Ji Soo; Yoon, Hae-Seong; Hong, Sang-Yong; Kim, Min-Jeong; Choi, Seihyun; Jo, Kiwon; Kim, Min-Hyeung; Kim, Jieun; Kim, Jung In; Park, Tae Kyo
PATENT ASSIGNEE(S): LG Life Sciences, Ltd., S. Korea
SOURCE: PCT Int. Appl., 255pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007058482	A1	20070524	WO 2006-KR4822	20061115

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: KR 2005-109398 A 20051116
OTHER SOURCE(S): MARPAT 147:9919
GI



I



II

AB Title compds. I [R1 = H, alkyl; A1, A2 = independently CH and derivs., N;

R2 = halo, CN, CF3, alkyl; Ar1 = 5-6 membered (hetero)arylene; X = independently H, halo, CN, OH, SH, CO2H, NH2, etc.; n = 0-5; E = O, S; Ar2 = H, 5-6 membered arylene; m = 0-4; Y = halo, CN, NO2, H, OH, NH2, etc.; and their pharmaceutically acceptable salts] were prepared as angiogenesis receptor tyrosine kinases inhibitors, in particular, VEGF receptor 2 kinase inhibitors. Thus, a multi-step synthesis was given for thiazolopyridine II. I were tested for inhibitory effect of receptor tyrosine kinase, and VEGF- or bFGF-dependent HUVEC (human umbilical vein endothelial cell) growth. Thus, I and their pharmaceutical compns. are useful for the treatment and prevention of angiogenesis-related diseases, particularly resulting from the unregulated or undesired KDR activity, such as cancers, psoriasis, rheumatoid arthritis, diabetic retinopathy, etc.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1215147 CAPLUS

DOCUMENT NUMBER: 146:155520

TITLE: Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents

AUTHOR(S): Pogrebniak, A.; Schemainda, I.; Azzam, K.; Pelka-Fleischer, R.; Nuessler, V.; Hasmann, M.

CORPORATE SOURCE: Department of Pathology, University of Ulm, Germany

SOURCE: European Journal of Medical Research (2006), 11(8), 313-321
CODEN: EJMRFL; ISSN: 0949-2321

PUBLISHER: I. Holzapfel Verlag GmbH

DOCUMENT TYPE: Journal

LANGUAGE: English

AB FK866 is a novel anticancer agent that was previously shown to interfere with NAD+ biosynthesis by inhibition of nicotinamide phosphoribosyltransferase and to initiate apoptosis in cancer cells. As NAD+ is involved in cellular DNA repair processes, the present in vitro study on THP-1 and K562 leukemia cells was conducted to investigate the cytotoxicity of FK866 combination treatment with various cytotoxic agents: the antimetabolite Ara-C, the DNA-intercalating agent daunorubicin and the alkylating compds. 1-methyl-3-nitro-1-nitrosoguanidinium (MNNG) and melphalan. Cell viability after drug exposure was assessed by propidium iodide (PI) staining. Non-cytotoxic concns. of FK866 (10-9M or less), applied simultaneously or 24 h before adding cytotoxic agents, caused a depletion in the intracellular NAD+ and - to a lesser extent - NADH levels in THP-1 cells. After 48 and 72 h treatment with daunorubicin and Ara-C, resp., increased cell death was observed in THP-1 cells that were pretreated with FK866, as compared to cells exposed to antineoplastic drugs alone. However, this effect was transient, and there was no difference in cell survival after 72 h incubation with daunorubicin or 96 h with Ara-C. Non-toxic concns. of FK866 added 8, 16, or 24 h before starting treatment with the PARP-activating agent MNNG synergistically decreased intracellular NAD+ contents, and increased MNNG-induced cytotoxicity both in THP-1 and K562 cells for at least 72 h. This effect was less pronounced when FK866 was used in combination with another alkylating agent, melphalan. The PARP inhibitor 3-aminobenzamide delayed MNNG-induced cytotoxicity by 24 h both in cells that were pretreated with FK866 and in non-pretreated cells. 48 H later, the protective effect of 3-aminobenzamide could no longer be observed, but FK866-pretreated cells retained increased sensitivity to MNNG. In conclusion, the chemosensitizing effect of FK866 on cell death induced by antineoplastic drugs was particularly obvious in combination with substances like MNNG that cause NAD+ depletion per se. It was less pronounced and only transiently measurable in combination with daunorubicin, Ara-C, and melphalan, resp. These results may indicate different levels of DNA damage implicated in the action of the cytotoxic agents used.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:880871 CAPLUS
DOCUMENT NUMBER: 145:413038
TITLE: Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866
AUTHOR(S): Kim, Mun-Kyoung; Lee, Jun Hyuck; Kim, Hun; Park, Soo Jeong; Kim, Sung Hyun; Kang, Gil Bu; Lee, Yun Sok; Kim, Jae Bum; Kim, Kyeong Kyu; Suh, Se Won; Eom, Soo Hyun
CORPORATE SOURCE: Department of Life Science, Gwangju Institute of Science & Technology, Gwangju, 500-712, S. Korea
SOURCE: Journal of Molecular Biology (2006), 362(1), 66-77
CODEN: JMOBAK; ISSN: 0022-2836
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Visfatin/pre-B cell colony-enhancing factor 1 (PBEF)/nicotinamide phosphoribosyltransferase (NAmPRTase) is a multifunctional protein having phosphoribosyltransferase, cytokine and adipokine activities. Originally isolated as a cytokine promoting the differentiation of B cell precursors, it was recently suggested to act as an insulin analog via the insulin receptor. Here, we describe the first crystal structure of visfatin in three different forms: apo and in complex with either NMN or the NAmPRTase inhibitor FK-866 which was developed as an anti-cancer agent, interferes with NAD biosynthesis, showing a particularly high specificity for NAmPRTase. The crystal structures of the complexes with either NMN or FK-866 show that the enzymic active site of visfatin is optimized for nicotinamide binding and that the nicotinamide-binding site is important for inhibition by FK-866. Interestingly, visfatin mimics insulin signaling by binding to the insulin receptor with an affinity similar to that of insulin and does not share the binding site with insulin on the insulin receptor. To predict binding sites, the potential interaction patches of visfatin and the L1-CR-L2 domain of insulin receptor were generated and analyzed. Although the relationship between the insulin-mimetic property and the enzymic function of visfatin has not been clearly established, our structures raise the intriguing possibility that the glucose metabolism and the NAD biosynthesis are linked by visfatin.
REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:663657 CAPLUS
DOCUMENT NUMBER: 145:202228
TITLE: Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents
AUTHOR(S): Khan, Javed A.; Tao, Xiao; Tong, Liang
CORPORATE SOURCE: Department of Biological Sciences, Columbia University, New York, NY, 10027, USA
SOURCE: Nature Structural & Molecular Biology (2006), 13(7), 582-588
CODEN: NSMBCU; ISSN: 1545-9993
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Nicotinamide phosphoribosyltransferase (NMPRTase) has a crucial role in the salvage pathway of NAD+ biosynthesis, and a potent inhibitor of NMPRTase, FK866, can reduce cellular NAD+ levels and induce apoptosis in tumors. The authors have determined the crystal structures at up to 2.1-Å resolution of human and murine NMPRTase, alone and in complex with the reaction product NMN or the inhibitor FK866. The structures suggest

that Asp219 is a determinant of substrate specificity of NMPRTase, which is confirmed by our mutagenesis studies. FK866 is bound in a tunnel at the interface of the NMPRTase dimer, and mutations in this binding site can abolish the inhibition by FK866. Contrary to current knowledge, the structures show that FK866 should compete directly with the nicotinamide substrate. Our structural and biochem. studies provide a starting point for the development of new anticancer agents.

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:636869 CAPLUS

DOCUMENT NUMBER: 145:103734

TITLE: Compositions comprising multiple antibiotic agents including a FabI inhibitor, methods of using the same, and preparation of the heterocycle FabI inhibitors

INVENTOR(S): Berman, Judd M.; Schmid, Molly B.; Mendlein, John D.; Kaplan, Nachum

PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.

SOURCE: U.S. Pat. Appl. Publ., 192 pp., which which
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006142265	A1	20060629	US 2005-231298	20050919
WO 2004082586	A2	20040930	WO 2004-IB1261	20040317
WO 2004082586	A3	20041223		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2003-455189P	P	20030317
US 2003-476970P	P	20030609
US 2003-488379P	P	20030718
WO 2004-IB1261	A2	20040317

OTHER SOURCE(S): MARPAT 145:103734

GI



II

AB The invention is directed to antibacterial compns. comprising an NADH (or NADPH)-dependent enoyl-acyl carrier protein (ACP) reductase (FabI, previously designated EnvM) inhibitor of formula (Y1)a-A-CH(R1)-NR1CO-L-R2

(I) and at least one other antibiotic/antibacterial agent [L = alkyl, alkenyl, or cycloalkyl which may be substituted by one or more R1; A = (un)substituted bicyclic heteroaryl of 8-12 atoms or a tricyclic ring of 12-16 atoms, containing 1-4 heteroatoms selected from N, S, and O; R1 = H, cyclo/alkyl, alk/aryl; R2 = heterocyclyl; a = 0-4; Y1 = -(CH2)n-CO-NR4R5; R4 = water solubilizing group; R5 = H, cyclo/alkyl; n = 0-4]. The antibacterial composition exhibits a synergistic antibacterial effect compared to its individual components. Thus, bromination of (S)-2-methyl-1,2,4,5-tetrahydropyrido[2,3-e][1,4]diazepin-3-one (preparation given), coupling of the bromide with N-methyl-N-[(3-methylbenzofuran-2-yl)methyl]acrylamide, and acidulation of the free base (no data) with TFA gave pyridodiazepine II•TFA. Selected I inhibited FabI with a Ki < 1 nM, an MIC (minimal inhibitory concentration) < 0.125 μg/mL, and an IC50 < 10 nM.

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:369236 CAPLUS
DOCUMENT NUMBER: 142:430124
TITLE: Preparation of 3-azabicyclo[3.1.0]hexane derivatives as glycine transporter inhibitors for enhancing cognition and treating psychoses
INVENTOR(S): Lowe, John A.; Mchardy, Stan
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037216	A2	20050428	WO 2004-US34083	20041014
WO 2005037216	A3	20050804		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004281794	A1	20050428	AU 2004-281794	20041014
CA 2542279	A1	20050428	CA 2004-2542279	20041014
US 2005096375	A1	20050505	US 2004-964931	20041014
EP 1680124	A2	20060719	EP 2004-795270	20041014
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1867338	A	20061122	CN 2004-80030044	20041014
BR 2004015356	A	20061212	BR 2004-15356	20041014
JP 2007508374	T	20070405	JP 2006-535348	20041014
IN 2006DN01426	A	20070810	IN 2006-DN1426	20060316
MX 2006PA04279	A	20060628	MX 2006-PA4279	20060417
NO 2006002193	A	20060515	NO 2006-2193	20060515
PRIORITY APPLN. INFO.:			US 2003-510846P P	20031014
			WO 2004-US34083 W	20041014

OTHER SOURCE(S): MARPAT 142:430124
GI



I

AB The present invention relates to substituted bicyclic [3.1.0]amines (shown as I; variables defined below; e.g. thiophene-2-carboxylic acid N-[(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl)methyl]-N-[3-fluoro-4-(morpholin-4-yl)phenyl]amide (II)), their pharmaceutically acceptable salts, pharmaceutical compns. thereof, and their use (no data) for the enhancement of cognition and the treatment of the pos. and neg. symptoms of schizophrenia and other psychoses in mammals, including humans. Compds. of the invention analyzed by an assay for their activity in inhibiting glycine reuptake in synaptosomes have IC50 values more potent than 10 μM; no values for individual examples of I are given. For I: y = H or (R100)k-R1-(R6)m; k = 0-1; l = 0-3; m = 1-3; n = 0-4; o = 0-1; p = 0-3; q = 0-4; r = 1-2; s = 0-4; t = 0-1; u = 1-3; v = 1-3; R100 is -CH2-, -CH(C1-C3)alkyl-, -C(O)- or -SO2-. R1 is -(C1-C6)alkyl, -(C3-C8)cycloalkyl, -(4 to 7 membered) heterocycloalkyl, -(CH2)l-(C6-C10 aryl) or -(5 to 10 membered) heteroaryl, or (5 to 10 membered) tetrahydroheteroaryl; each R6 = H, halo, -(C1-C6) alkyl-B, (C1-C7) alkoxy-D, (C2-C4)alkenoxy, (C1-C6)alkyl-OH, -OH, CN, -NO2, -CR7R8R9, -NR20R21, -NHCOalkyl(C1-C3), NHSO2alkyl(C1-C3), C(O)OR22, -R23C(O)OR22, -C(O)NH2, phenyl-E, phenoxy-F, morpholine, -NR20R21, aryl, heteroaryl, -SR24, and -SO2R25; B and D = H, OH, Ph, di-Ph or trifluoro; E and F = H, alkyl, or halo. R2 and R3 = H or (C1-C3)alkyl; R4 and R5 = H or (C1-C3) alkyl; or R4 and R5 taken together form a double bond to an O to form (C:O), or R4 and R5 are connected with 2 to 4 C atoms to form a 3-5 member carbocyclic ring; A is H or (C1-C3)alkyl-(R28)n; R28 = (C1-C3)alkoxy, -OH, -NR12R13 or -NHC(O)(C1-C4)alkyl; X is a bond, -CH2(R29)p, -C(O) or -SO2; R29 is -(C1-C3)alkyl; W is alkyl, -(C3-C6)cycloalkyl, -(3 to 7 membered) heterocycloalkyl, -(3 to 7 membered) heterocycloalkyl with 1 or 2 C:O groups, Ph, or -(5 to 7 member) heteroaryl or heterocyclic; R30 is -(C1-C4)alkyl, -(C1-C3)alkoxy, CN, -F, -Cl, -Br, -I, -NR18R19, -NHC(O)R18, -SCH3 or -C(O)CH3. Q is a bond, -CH(R31)r, -C(O) or SO2; R31 = H or (C1-C3)alkyl; Z is -(C1-C8)alkyl, -(C3-C8)cycloalkyl, -(4 to 8 member) heterocycloalkyl, Ph or -(5 to 7 membered) heteroaryl or heterocyclic; R14 is F, Cl, Br, I, V, H, -NR16R17, -OR16, -C(O)NR16R17, -(SO2)NR16R17, or NR32C:O-R33; R15 is -(C1-C3)alkyl, -(C1-C3)alkoxy, -F, -Br, -Cl, -I -OH or CN; V is -(C3-C8)cycloalkyl, -(C1-C5)alkyl, (5 to 7 membered) heterocycloalkyl, (5 to 7 membered)heterocycloalkyl substituted with 1 or 2 C:O groups or 1, 2, or 3-(C1-C5)alkyl groups; addnl. details are given in the claims. Although the methods of preparation are not claimed, 6 example prepns. are included. For example, II was prepared in 5 steps starting from (3-azabicyclo[3.1.0]hex-6-yl)methanol hydrochloride and involving 6-hydroxymethyl-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-Bu ester, 6-[[[3-fluoro-4-(morpholin-4-yl)phenyl]amino]methyl]-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-Bu ester, 6-[[[3-fluoro-4-(morpholin-4-yl)phenyl][(thien-2-yl)carbonyl]amino]methyl]-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-Bu ester and thiophene-2-carboxylic acid N-[(3-azabicyclo[3.1.0]hex-6-yl)methyl]-N-[3-fluoro-4-(morpholin-4-yl)phenyl]amide trifluoroacetate as intermediates.

L6 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:799437 CAPLUS
DOCUMENT NUMBER: 141:314353
TITLE: Compositions comprising multiple antibiotic agents including a FabI inhibitor, methods of using the same, and preparation of the heterocycle FabI inhibitors
INVENTOR(S): Berman, Judd M.; Schmid, Molly B.; Mendlein, John D.; Kaplan, Nachum
PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.
SOURCE: PCT Int. Appl., 311 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004082586	A2	20040930	WO 2004-IB1261	20040317
WO 2004082586	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2519429	A1	20040930	CA 2004-2519429	20040317
EP 1608377	A2	20051228	EP 2004-721257	20040317
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
JP 2006523207	T	20061012	JP 2006-506526	20040317
US 2006142265	A1	20060629	US 2005-231298	20050919

PRIORITY APPLN. INFO.:

US 2003-455189P	P	20030317
US 2003-476970P	P	20030609
US 2003-488379P	P	20030718
WO 2004-IB1261	W	20040317

OTHER SOURCE(S): MARPAT 141:314353
GI



I

AB The invention is directed to antibacterial compns. comprising an NADH (or NADPH)-dependent enoyl-acyl carrier protein (ACP) reductase (FabI, previously designated EnvM) inhibitor of formula (Y1)a-A-CH(R1)-NR1CO-L-R2 (I) and at least one other antibiotic/antibacterial agent [L = alkyl, alkenyl, or cycloalkyl which may be substituted by one or more R1; A = (un)substituted bicyclic heteroaryl of 8-12 atoms or a tricyclic ring of 12-16 atoms, containing 1-4 heteroatoms selected from N, S, and O; R1 = cyclo/alkyl, alk/aryl; R2 = heterocyclyl; a = 0-4; Y1 = -(CH2)n-CO-NR4R5; R4 = water solubilizing group; R5 = H, cyclo/alkyl; n = 0-4]. The antibacterial composition exhibits a synergistic antibacterial effect compared to its individual components. Thus, reacting 7-Bromo-3,3-dimethyl-1,3,4,5-

tetrahydropyrido[2,3-e][1,4]diazepin-2-one (preparation given) with N-Methyl-N-[(3-methylbenzo[b]thiophen-2-yl)methyl]acrylamide (preparation given), followed by acidulation gave diazepinone salt II•HCl. Selected I inhibited FabI with a Ki < 1 nM, an MIC (minimal inhibitory concentration) < 0.125 μg/mL, and an IC50 < 10 nM.

L6 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:885670 CAPLUS
DOCUMENT NUMBER: 140:174633
TITLE: FK866, a Highly Specific Noncompetitive Inhibitor of Nicotinamide Phosphoribosyltransferase, Represents a Novel Mechanism for Induction of Tumor Cell Apoptosis
AUTHOR(S): Hasmann, Max; Schemainda, Isabel
CORPORATE SOURCE: Fujisawa GmbH, Munich, 81673, Germany
SOURCE: Cancer Research (2003), 63(21), 7436-7442
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Deregulation of apoptosis, the physiol. form of cell death, is closely associated with immunol. diseases and cancer. Apoptosis is activated either by death receptor-driven or mitochondrial pathways, both of which may provide potential targets for novel anticancer drugs. Although several ligands stimulating death receptors have been described, the actual mol. events triggering the mitochondrial pathway are largely unknown. Here, we show initiation of apoptosis by gradual depletion of the intracellular coenzyme NAD+. We identified the first low mol. weight compound, designated FK866, which induces apoptosis by highly specific, noncompetitive inhibition of nicotinamide phosphoribosyltransferase (NAPRT), a key enzyme in the regulation of NAD+ biosynthesis from the natural precursor nicotinamide. Interference with this enzyme does not primarily intoxicate cells because the mitochondrial respiratory activity and the NAD+-dependent redox reactions involved remain unaffected as long as NAD+ is not effectively depleted by catabolic reactions. Certain tissues, however, have a high turnover of NAD+ through its cleavage by enzymes like poly(ADP-ribose) polymerase. Such cells often rely on the more readily available nicotinamide pathway for NAD+ synthesis and undergo apoptosis after inhibition of NAPRT, whereas cells effectively using the nicotinic acid pathway for NAD+ synthesis remain unaffected. In support of this concept, FK866 effectively induced delayed cell death by apoptosis in HepG2 human liver carcinoma cells with an IC50 of .apprx.1 nM, did not directly inhibit mitochondrial respiratory activity, but caused gradual NAD+ depletion through specific inhibition of NAPRT. This enzyme, when partially purified from K562 human leukemia cells, was noncompetitively inhibited by FK866, and the inhibitor consts. were calculated to be 0.4 nM for the enzyme/substrate complex (Ki) and 0.3 nM for the free enzyme (Ki'), resp. Nicotinic acid and nicotinamide were both found to have antidote potential for the cellular effects of FK866. FK866 may be used for treatment of diseases implicating deregulated apoptosis such as cancer for immunosuppression or as a sensitizer for genotoxic agents. Furthermore, it may provide an important tool for investigation of the mol. triggers of the mitochondrial pathway leading to apoptosis through enabling temporal separation of NAD+ decrease from ATP breakdown and apoptosis by several days.
REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:706352 CAPLUS
DOCUMENT NUMBER: 133:276324
TITLE: Inhibitors of cellular nicotinamide mononucleotide formation, therapeutic use thereof,and identification and metabolic methods
INVENTOR(S): Biedermann, Elfi; Eisenburger, Rolf; Hasmann, Max;

Loser, Roland; Rattel, Benno; Reiter, Friedemann; Schein, Barbara; Schemainda, Isabel; Schulz, Michael; Seibel, Klaus; Vogt, Klaus; Wosikowski, Katja

PATENT ASSIGNEE(S): Klinge Pharma G.m.b.H., Germany
SOURCE: Ger. Offen., 20 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19908483	A1	20001005	DE 1999-19908483	19990226
PRIORITY APPLN. INFO.:			DE 1999-19908483	19990226

AB Biol. active substances are described which inhibit the cellular formation of NMN, an essential intermediate in NAD(P) biosynthesis in the cell. These substances can be used for a pharmaceutical composition for the treatment of cancer, leukemia, or for Immunosuppression. Addnl., methods are described for the identification of such substances and for the investigation of a given cell type for its dependence on nicotinamide as a precursor in NAD synthesis.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:690954 CAPLUS
DOCUMENT NUMBER: 131:307106
TITLE: Use of vitamin PP compounds as cytoprotective agents in chemotherapy

INVENTOR(S): Biedermann, Elfi; Hasmann, Max; Loser, Roland; Rattel, Benno; Reiter, Friedemann; Schein, Barbara; Schemainda, Isabel; Seibel, Klaus; Vogt, Klaus; Wosikowski, Katja

PATENT ASSIGNEE(S): Klinge Pharma GmbH, Germany
SOURCE: PCT Int. Appl., 145 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9953920	A1	19991028	WO 1999-EP2686	19990421
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19818044	A1	19991028	DE 1998-19818044	19980422
EP 1031564	A1	20000830	EP 1999-103814	19990226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 9939282	A	19991108	AU 1999-39282	19990421
EP 1079832	A1	20010307	EP 1999-922119	19990421
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002512190	T	20020423	JP 2000-544324	19990421
AT 311186	T	20051215	AT 1999-922119	19990421
ES 2253890	T3	20060601	ES 1999-922119	19990421
WO 2000050399	A1	20000831	WO 2000-EP1628	20000228
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,				

CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1154998	A1	20011121	EP 2000-907642	20000228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002537380	T	20021105	JP 2000-600982	20000228
EP 1816124	A2	20070808	EP 2007-10337	20000228
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 2002160968	A1	20021031	US 2001-935772	20010823
US 6506572	B2	20030114		

PRIORITY APPLN. INFO.:

DE 1998-19818044	A	19980422
EP 1999-103814	A	19990226
WO 1999-EP2686	W	19990421
EP 2000-907642	A3	20000228
WO 2000-EP1628	W	20000228

OTHER SOURCE(S): MARPAT 131:307106

AB The invention relates to the use of vitamin PP compds. and/or compds. with anti-pellagra activity such as for example nicotinic acid (niacin), and nicotinamide (niacin-amide, vitamin PP, vitamin B3) for the reduction, elimination or prevention of side-effects of different degrees as well as for neutralization of acute side-effects in immunosuppressive or cancerostatic chemotherapy or diagnosis, especially with substituted pyridine carboxamides, as well as combination medicaments with an amount of compds. with vitamin B3 and/or anti-pellagra activity and chemotherapeutic agents are especially considered in the mentioned chemotherapies and indications. Nicotinamide at 500 mg/kg twice daily protected mice treated i.p. with antitumor N-[4-(1-diphenylmethylpiperidin-4-yl)butyl]-3-(pyridin-3-yl)propionamide. There were no deaths in the nicotinamide -treated mice and the strong reduction of leukocytes was completely prevented.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 18 USPATFULL on STN

ACCESSION NUMBER: 2007:177955 USPATFULL

TITLE: THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS

INVENTOR(S): Betschmann, Patrick, Shrewsbury, MA, UNITED STATES
Burchat, Andrew F., Shrewsbury, MA, UNITED STATES
Calderwood, David J., Framingham, MA, UNITED STATES
Curtin, Michael L., Pleasant Prairie, WI, UNITED STATES
Davidsen, Steven K., Libertyville, IL, UNITED STATES
Davis, Heather M., Oxford, MA, UNITED STATES
Frey, Robin R., Libertyville, IL, UNITED STATES
Heyman, Howard R., Deerfield, IL, UNITED STATES
Hirst, Gavin C., Princeton, MA, UNITED STATES
Hrnciar, Peter, Hamden, CT, UNITED STATES
Michaelides, Michael R., Libertyville, IL, UNITED STATES
Muckey, Melanie A., Trevor, WI, UNITED STATES
Mullen, Kelly D., Charlton, MA, UNITED STATES
Rafferty, Paul, Westborough, MA, UNITED STATES
Wada, Carol K., Gurnee, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007155776	A1	20070705
APPLICATION INFO.:	US 2007-675183	A1	20070215 (11)

RELATED APPLN. INFO.: Division of Ser. No. US 2004-899168, filed on 26 Jul 2004, GRANTED, Pat. No. US 7202363

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-567703P	20040503 (60)
	US 2003-489734P	20030724 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Robert DeBerardine, D-377/AP6A-1, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL, 60064-6008, US
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 15633
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula ##STR1## are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2006:215750 USPATFULL
TITLE: Heterocyclic compounds, methods of making them and their use in therapy
INVENTOR(S): Berman, Judd, Toronto, CANADA
Sampson, Peter, Ontario, CANADA
Pauls, Heinz W., Ontario, CANADA
Ramnauth, Jailall, Ontario, CANADA
Douglas, David, Manning, NY, UNITED STATES
Surman, Matthew David, Albany, NY, UNITED STATES
Xie, Dejian, Glenmount, NY, UNITED STATES
Decornez, Helene Yvonne, Clifton Park, NY, UNITED STATES
PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Toronto, ON, CANADA, M5J1V6 (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006183908	A1	20060817	
APPLICATION INFO.:	US 2003-537747	A1	20031205	(10)
	WO 2003-US38706		20031205	
			20060327	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-431406P	20021206 (60)
	US 2003-465583P	20030425 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 7935
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In part, the present invention is directed to antibacterial compounds of formula (I) wherein A is a bicyclic heteroaryl ring or a tricyclic ring and R.sub.2 is an heterocyclic residue; L is a bond, or L is alkyl, alkenyl or cycloalkyl. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2006:167754 USPATFULL
TITLE: Compositions comprising multiple bioactive agents, and

methods of using the same
INVENTOR(S): Berman, Judd M., Toronto, CANADA
Schmid, Molly B., Toronto, CANADA
Mendlein, John D., Encinitas, CA, UNITED STATES
Kaplan, Nachum, Toronto, CANADA
PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Toronto, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006142265	A1	20060629
APPLICATION INFO.:	US 2005-231298	A1	20050919 (11)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2004-IB1261, filed on 17 Mar 2004, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-455189P	20030317 (60)
	US 2003-476970P	20030609 (60)
	US 2003-488379P	20030718 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 15944
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In part, the present invention is directed to compositions comprising a FabI inhibitor and at least one other bioactive agent. In another part, the present invention is directed to antibacterial compositions comprising a compound of formulas I-III and at least one other antibacterial agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2005:112290 USPATFULL
TITLE: Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
INVENTOR(S): McHardy, Stanton, Coventry, RI, UNITED STATES
Lowe, John A., Stonington, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005096375	A1	20050505
APPLICATION INFO.:	US 2004-964931	A1	20041014 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-510846P	20031014 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SCULLY SCOTT MURPHY & PRESSER, PC, 400 GARDEN CITY PLAZA, SUITE 300, GARDEN CITY, NY, 11530, US
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 2435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a series of substituted bicyclic[3.1.0]amines of the Formula I: ##STR1## wherein A, B, D, Q, V, W, X, Y, Z, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.14, R.sup.15, R.sup.30. o, p, s,t and q are as defined in the specification, their pharmaceutically acceptable salts, pharmaceutical compositions

thereof, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2005:50547 USPATFULL
TITLE: Thienopyridine and furopyridine kinase inhibitors
INVENTOR(S): Betschmann, Patrick, Shrewsbury, MA, UNITED STATES
Burchat, Andrew F., Shrewsbury, MA, UNITED STATES
Calderwood, David J., Framingham, MA, UNITED STATES
Curtin, Michael L., Pleasant Prairie, WI, UNITED STATES
Davidsen, Steven K., Libertyville, IL, UNITED STATES
Davis, Heather M., Oxford, MA, UNITED STATES
Frey, Robin R., Libertyville, IL, UNITED STATES
Heyman, Howard R., Deerfield, IL, UNITED STATES
Hirst, Gavin C., Princeton, MA, UNITED STATES
Hrnciar, Peter, Hamden, CT, UNITED STATES
Michaelides, Michael R., Libertyville, IL, UNITED STATES
Muckey, Melanie A., Trevor, WI, UNITED STATES
Rafferty, Paul, Westborough, MA, UNITED STATES
Wada, Carol K., Gurnee, IL, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005043347	A1	20050224	
	US 7202363	B2	20070410	
APPLICATION INFO.:	US 2004-899168	A1	20040726	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2004-567703P	20040503	(60)
	US 2003-489734P	20030724	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROBERT DEBERARDINE, ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 15845
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula ##STR1##

are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 16 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2005:31507 USPATFULL
TITLE: Thienopyridine and furopyridine kinase inhibitors
INVENTOR(S): Betschmann, Patrick, Shrewsbury, MA, UNITED STATES
Burchat, Andrew F., Shrewsbury, MA, UNITED STATES
Calderwood, David J., Framingham, MA, UNITED STATES
Curtin, Michael L., Pleasant Prairie, WI, UNITED STATES
Davidsen, Steven K., Libertyville, IL, UNITED STATES
Davis, Heather M., Oxford, MA, UNITED STATES
Frey, Robin R., Libertyville, IL, UNITED STATES
Heyman, Howard R., Deerfield, IL, UNITED STATES
Hirst, Gavin C., Princeton, MA, UNITED STATES
Hrnciar, Peter, Hamden, CT, UNITED STATES
Michaelides, Michael R., Libertyville, IL, UNITED

STATES
Muckey, Melanie A., Trevor, WI, UNITED STATES
Rafferty, Paul, Westborough, MA, UNITED STATES
Wada, Carol K., Gurnee, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005026944	A1	20050203
APPLICATION INFO.:	US 2004-838132	A1	20040503 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-626092, filed on 24 Jul 2003, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROBERT DEBERARDINE, ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 10032
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula ##STR1##

are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2005:24070 USPATFULL
TITLE: Thienopyridine kinase inhibitors
INVENTOR(S): Betschmann, Patrick, Shrewsbury, MA, UNITED STATES
Burchat, Andrew, Shrewsbury, MA, UNITED STATES
Calderwood, David, Framingham, MA, UNITED STATES
Curtin, Michael L., Pleasant Prairie, WI, UNITED STATES
Davidsen, Steven K., Libertyville, IL, UNITED STATES
Davis, Heather M., Oxford, MA, UNITED STATES
Frey, Robin R., Libertyville, IL, UNITED STATES
Heyman, Howard R., Deerfield, IL, UNITED STATES
Hirst, Gavin, Princeton, MA, UNITED STATES
Hrnciar, Peter, Hamden, CT, UNITED STATES
Michaelides, Michael, Libertyville, IL, UNITED STATES
Rafferty, Paul, Westborough, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005020619	A1	20050127
APPLICATION INFO.:	US 2003-626092	A1	20030724 (10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROBERT DEBERARDINE, ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 7164
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula ##STR1##

are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2002:288098 USPATFULL

TITLE: Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy

INVENTOR(S): Biedermann, Elfi, Vaterstetten, GERMANY, FEDERAL REPUBLIC OF
Eisenburger, Rolf, Kirchseeon, GERMANY, FEDERAL REPUBLIC OF
Hasmann, Max, Neuried, GERMANY, FEDERAL REPUBLIC OF
Loser, Roland, Feldafing, GERMANY, FEDERAL REPUBLIC OF
Rattel, Benno, Munich, GERMANY, FEDERAL REPUBLIC OF
Reiter, Friedemann, Putzbrunn, GERMANY, FEDERAL REPUBLIC OF
Schein, Barbara, Neufahrn, GERMANY, FEDERAL REPUBLIC OF
Schemainda, Isabel, Munich, GERMANY, FEDERAL REPUBLIC OF
Schulz, Michael, Aschheim, GERMANY, FEDERAL REPUBLIC OF
Seibel, Klaus, Grafelfing, GERMANY, FEDERAL REPUBLIC OF
Vogt, Klaus, Munich, GERMANY, FEDERAL REPUBLIC OF
Wosikowski, Katja, Poing, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Klinge Pharma GmbH (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002160968	A1	20021031
	US 6506572	B2	20030114
APPLICATION INFO.:	US 2001-935772	A1	20010823 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2000-EP1628, filed on 28 Feb 2000, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1999-103814	19990226

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FITCH EVEN TABIN AND FLANNERY, 120 SOUTH LA SALLE STREET, SUITE 1600, CHICAGO, IL, 60603-3406
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 28 Drawing Page(s)
LINE COUNT: 3127
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB New biologically active compounds are described which inhibit the cellular formation of niacinamide mononucleotide, and essential intermediate of the NAD(P) biosynthesis in the cell. These compounds can represent the active ingredient of a pharmaceutical composition for the treatment of cancers, leukaemias or for immunosuppression. Furthermore, screening methods are described as a tool for detecting the above active compounds, and for examination of a given cell type for its dependency on niacinamide as a precursor for NAD synthesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> file uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	100.24	272.55

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-12.48	-12.48

FILE 'USPATFULL' ENTERED AT 12:25:19 ON 21 AUG 2007

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 21 Aug 2007 (20070821/PD)

FILE LAST UPDATED: 21 Aug 2007 (20070821/ED)
HIGHEST GRANTED PATENT NUMBER: US7260849
HIGHEST APPLICATION PUBLICATION NUMBER: US2007192920
CA INDEXING IS CURRENT THROUGH 21 Aug 2007 (20070821/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 21 Aug 2007 (20070821/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2007
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2007

=> s l2
L7 17 L2

=> d l7 1-17 ibib, abs

L7 ANSWER 1 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2007:177955 USPATFULL
TITLE: THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS
INVENTOR(S): Betschmann, Patrick, Shrewsbury, MA, UNITED STATES
Burchat, Andrew F., Shrewsbury, MA, UNITED STATES
Calderwood, David J., Framingham, MA, UNITED STATES
Curtin, Michael L., Pleasant Prairie, WI, UNITED STATES
Davidsen, Steven K., Libertyville, IL, UNITED STATES
Davis, Heather M., Oxford, MA, UNITED STATES
Frey, Robin R., Libertyville, IL, UNITED STATES
Heyman, Howard R., Deerfield, IL, UNITED STATES
Hirst, Gavin C., Princeton, MA, UNITED STATES
Hrnciar, Peter, Hamden, CT, UNITED STATES
Michaelides, Michael R., Libertyville, IL, UNITED STATES
Muckey, Melanie A., Trevor, WI, UNITED STATES
Mullen, Kelly D., Charlton, MA, UNITED STATES
Rafferty, Paul, Westborough, MA, UNITED STATES
Wada, Carol K., Gurnee, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007155776	A1	20070705
APPLICATION INFO.:	US 2007-675183	A1	20070215 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2004-899168, filed on 26 Jul 2004, GRANTED, Pat. No. US 7202363		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-567703P	20040503 (60)
	US 2003-489734P	20030724 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Robert DeBerardine, D-377/AP6A-1, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL, 60064-6008, US
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 15633
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula ##STR1## are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2007:162821 USPATFULL
TITLE: Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives
INVENTOR(S): Biedermann, Elfi, Vaterstetten, GERMANY, FEDERAL

REPUBLIC OF
Hasmann, Max, Neuried, GERMANY, FEDERAL REPUBLIC OF
Loser, Roland, Feldafing, GERMANY, FEDERAL REPUBLIC OF
Rattel, Benno, Munich, GERMANY, FEDERAL REPUBLIC OF
Reiter, Friedemann, Putzbrunn, GERMANY, FEDERAL REPUBLIC OF
Schein, Barbara, Neufahrn, GERMANY, FEDERAL REPUBLIC OF
Seibel, Klaus, Grafelfing, GERMANY, FEDERAL REPUBLIC OF
Vogt, Klaus, Munich, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007142377	A1	20070621
APPLICATION INFO.:	US 2007-678980	A1	20070226 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-213952, filed on 5 Aug 2002, PENDING Continuation of Ser. No. US 1999-242540, filed on 18 Feb 1999, ABANDONED A 371 of International Ser. No. WO 1997-EP3245, filed on 20 Jun 1997

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19624659	19960620

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FITCH EVEN TABIN AND FLANNERY, 120 SOUTH LA SALLE STREET, SUITE 1600, CHICAGO, IL, 60603-3406, US
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
LINE COUNT: 4276
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a new pyridyl alkene and pyridyl alkine acid amides according to the general formula (I) ##STR1## as well as methods for their production, medicaments containing these compounds as well as their medical use, especially in the treatment of tumors or for immunosuppression.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2006:215750 USPATFULL
TITLE: Heterocyclic compounds, methods of making them and their use in therapy
INVENTOR(S): Berman, Judd, Toronto, CANADA
Sampson, Peter, Ontario, CANADA
Pauls, Heinz W., Ontario, CANADA
Ramnauth, Jailall, Ontario, CANADA
Douglas, David, Manning, NY, UNITED STATES
Surman, Matthew David, Albany, NY, UNITED STATES
Xie, Dejian, Glenmount, NY, UNITED STATES
Decornez, Helene Yvonne, Clifton Park, NY, UNITED STATES
PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Toronto, ON, CANADA, M5J1V6 (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006183908	A1	20060817	
APPLICATION INFO.:	US 2003-537747	A1	20031205	(10)
	WO 2003-US38706		20031205	
			20060327	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-431406P	20021206 (60)
	US 2003-465583P	20030425 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 7935
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In part, the present invention is directed to antibacterial compounds of formula (I) wherein A is a bicyclic heteroaryl ring or a tricyclic ring and R.sub.2 is an heterocyclic residue; L is a bond, or L is alkyl, alkenyl or cycloalkyl. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2006:167754 USPATFULL
TITLE: Compositions comprising multiple bioactive agents, and methods of using the same
INVENTOR(S): Berman, Judd M., Toronto, CANADA
Schmid, Molly B., Toronto, CANADA
Mendlein, John D., Encinitas, CA, UNITED STATES
Kaplan, Nachum, Toronto, CANADA
PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Toronto, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006142265	A1	20060629
APPLICATION INFO.:	US 2005-231298	A1	20050919 (11)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2004-IB1261, filed on 17 Mar 2004, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-455189P	20030317 (60)
	US 2003-476970P	20030609 (60)
	US 2003-488379P	20030718 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 15944
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB In part, the present invention is directed to compositions comprising a FabI inhibitor and at least one other bioactive agent. In another part, the present invention is directed to antibacterial compositions comprising a compound of formulas I-III and at least one other antibacterial agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2006:61249 USPATFULL
TITLE: Use of pyridly amides as inhibitors of angiogenesis
INVENTOR(S): Biedermann, Elfi, Vaterstetten, GERMANY, FEDERAL REPUBLIC OF
Loser, Roland, Feidafing, GERMANY, FEDERAL REPUBLIC OF
Rattel, Benno, Munich, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006052419	A1	20060309	
APPLICATION INFO.:	US 2003-509362	A1	20030324	(10)
	WO 2003-EP3060		20030324	
			20050415	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2002-6697	20020327

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HELLER EHRMAN LLP, 275 MIDDLEFIELD ROAD, MENLO PARK, CA, 94025-3506, US
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1-14
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 1137
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of derivatives of Formula I in the manufacture of a pharmaceutical composition for the treatment of a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred, and to the prevention thereof. (I) ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2005:112290 USPATFULL
TITLE: Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
INVENTOR(S): McHardy, Stanton, Coventry, RI, UNITED STATES
Lowe, John A., Stonington, CT, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005096375	A1	20050505	
APPLICATION INFO.:	US 2004-964931	A1	20041014	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-510846P	20031014 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SCULLY SCOTT MURPHY & PRESSER, PC, 400 GARDEN CITY PLAZA, SUITE 300, GARDEN CITY, NY, 11530, US
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 2435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a series of substituted bicyclic[3.1.0]amines of the Formula I: ##STR1## wherein A, B, D, Q, V, W, X, Y, Z, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.14, R.sup.15, R.sup.30. o, p, s,t and q are as defined in the specification, their pharmaceutically acceptable salts, pharmaceutical compositions thereof, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2005:50547 USPATFULL
TITLE: Thienopyridine and furopyridine kinase inhibitors
INVENTOR(S): Betschmann, Patrick, Shrewsbury, MA, UNITED STATES
Burchat, Andrew F., Shrewsbury, MA, UNITED STATES
Calderwood, David J., Framingham, MA, UNITED STATES

Curtin, Michael L., Pleasant Prairie, WI, UNITED STATES
Davidsen, Steven K., Libertyville, IL, UNITED STATES
Davis, Heather M., Oxford, MA, UNITED STATES
Frey, Robin R., Libertyville, IL, UNITED STATES
Heyman, Howard R., Deerfield, IL, UNITED STATES
Hirst, Gavin C., Princeton, MA, UNITED STATES
Hrnciar, Peter, Hamden, CT, UNITED STATES
Michaelides, Michael R., Libertyville, IL, UNITED STATES
Muckey, Melanie A., Trevor, WI, UNITED STATES
Rafferty, Paul, Westborough, MA, UNITED STATES
Wada, Carol K., Gurnee, IL, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005043347	A1	20050224	
	US 7202363	B2	20070410	
APPLICATION INFO.:	US 2004-899168	A1	20040726	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2004-567703P	20040503	(60)
	US 2003-489734P	20030724	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROBERT DEBERARDINE, ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 15845
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula ##STR1##

are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2005:31507 USPATFULL
TITLE: Thienopyridine and furopyridine kinase inhibitors
INVENTOR(S): Betschmann, Patrick, Shrewsbury, MA, UNITED STATES
Burchat, Andrew F., Shrewsbury, MA, UNITED STATES
Calderwood, David J., Framingham, MA, UNITED STATES
Curtin, Michael L., Pleasant Prairie, WI, UNITED STATES
Davidsen, Steven K., Libertyville, IL, UNITED STATES
Davis, Heather M., Oxford, MA, UNITED STATES
Frey, Robin R., Libertyville, IL, UNITED STATES
Heyman, Howard R., Deerfield, IL, UNITED STATES
Hirst, Gavin C., Princeton, MA, UNITED STATES
Hrnciar, Peter, Hamden, CT, UNITED STATES
Michaelides, Michael R., Libertyville, IL, UNITED STATES
Muckey, Melanie A., Trevor, WI, UNITED STATES
Rafferty, Paul, Westborough, MA, UNITED STATES
Wada, Carol K., Gurnee, IL, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005026944	A1	20050203	
APPLICATION INFO.:	US 2004-838132	A1	20040503	(10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-626092, filed on 24 Jul 2003, PENDING
DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROBERT DEBERARDINE, ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 10032
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula ##STR1##

are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2005:24070 USPATFULL
TITLE: Thienopyridine kinase inhibitors
INVENTOR(S): Betschmann, Patrick, Shrewsbury, MA, UNITED STATES
Burchat, Andrew, Shrewsbury, MA, UNITED STATES
Calderwood, David, Framingham, MA, UNITED STATES
Curtin, Michael L., Pleasant Prairie, WI, UNITED STATES
Davidsen, Steven K., Libertyville, IL, UNITED STATES
Davis, Heather M., Oxford, MA, UNITED STATES
Frey, Robin R., Libertyville, IL, UNITED STATES
Heyman, Howard R., Deerfield, IL, UNITED STATES
Hirst, Gavin, Princeton, MA, UNITED STATES
Hrnciar, Peter, Hamden, CT, UNITED STATES
Michaelides, Michael, Libertyville, IL, UNITED STATES
Rafferty, Paul, Westborough, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005020619	A1	20050127	
APPLICATION INFO.:	US 2003-626092	A1	20030724	(10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROBERT DEBERARDINE, ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 7164
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds having the formula ##STR1##

are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2004:228219 USPATFULL
TITLE: New pyridyl alkane acid amides as cytostatics and immunosuppressives
INVENTOR(S): Biedermann, Elfi, Vaterstetten, GERMANY, FEDERAL REPUBLIC OF
Hasmann, Max, Neuried, GERMANY, FEDERAL REPUBLIC OF
Loser, Roland, Feldafing, GERMANY, FEDERAL REPUBLIC OF
Rattel, Benno, Munich, GERMANY, FEDERAL REPUBLIC OF
Reiter, Friedemann, Putzbrunn, GERMANY, FEDERAL REPUBLIC OF
Schein, Barbara, Neufahrn, GERMANY, FEDERAL REPUBLIC OF
Seibel, Klaus, Grafelfing, GERMANY, FEDERAL REPUBLIC OF
Vogt, Klaus, Munich, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Klinge Pharma GmbH (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004176605	A1	20040909
APPLICATION INFO.:	US 2003-683509	A1	20031010 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-208656, filed on 30 Jul 2002, ABANDONED Continuation of Ser. No. US 1998-216075, filed on 18 Dec 1998, GRANTED, Pat. No. US 6444823 Continuation of Ser. No. WO 1997-EP3243, filed on 20 Jun 1997, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19624704	19960620

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FITCH EVEN TABIN AND FLANNERY, 120 SOUTH LA SALLE STREET, SUITE 1600, CHICAGO, IL, 60603-3406
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
LINE COUNT: 4640
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to new pyridyl alkane acid amides according to general formula (I) as well as methods for their production, medicaments containing these compounds as well as their medical use, especially in the treatment of tumors or for immunosuppression. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 11 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2004:39319 USPATFULL
TITLE: Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
INVENTOR(S): Biedermann, Elfi, Vaterstetten, GERMANY, FEDERAL REPUBLIC OF
Hasmann, Max, Neuried, GERMANY, FEDERAL REPUBLIC OF
Loser, Roland, Feldafing, GERMANY, FEDERAL REPUBLIC OF
Rattel, Benno, Munich, GERMANY, FEDERAL REPUBLIC OF
Reiter, Friedemann, Putzbrunn, GERMANY, FEDERAL REPUBLIC OF
Schein, Barbara, Neufahrn, GERMANY, FEDERAL REPUBLIC OF
Seibel, Klaus, Grafelfing, GERMANY, FEDERAL REPUBLIC OF
Vogt, Klaus, Munich, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Klinge Pharma GmbH (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004029861	A1	20040212
APPLICATION INFO.:	US 2002-208253	A1	20020730 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-216482, filed on 18 Dec 1998, GRANTED, Pat. No. US 6451816 Continuation of Ser. No. WO 1997-EP3244, filed on 20 Jun 1997, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1997-19624668	19970620

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FITCH EVEN TABIN AND FLANNERY, 120 SOUTH LA SALLE STREET, SUITE 1600, CHICAGO, IL, 60603-3406
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 5504

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of pharmacologically valuable pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides according to general formula (I) in the treatment of tumors or for immunosuppression. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2004:13445 USPATFULL

TITLE: Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immuno-suppressives

INVENTOR(S): Biedermann, Elfi, Vaterstetten, GERMANY, FEDERAL REPUBLIC OF
Hasmann, Max, Neuried, GERMANY, FEDERAL REPUBLIC OF
Loser, Roland, Feldafing, GERMANY, FEDERAL REPUBLIC OF
Rattel, Benno, Munich, GERMANY, FEDERAL REPUBLIC OF
Reiter, Friedemann, Putzbrunn, GERMANY, FEDERAL REPUBLIC OF
Schein, Barbara, Neufahrn, GERMANY, FEDERAL REPUBLIC OF
Seibel, Klaus, Grafelfing, GERMANY, FEDERAL REPUBLIC OF
Vogt, Klaus, Munich, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Klinge Pharma GmbH (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009967	A1	20040115
APPLICATION INFO.:	US 2002-208656	A1	20020730 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-216075, filed on 18 Dec 1998, GRANTED, Pat. No. US 6444823 Continuation of Ser. No. WO 1997-EP3243, filed on 20 Jun 1997, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19624704	19960620

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FITCH EVEN TABIN AND FLANNERY, 120 SOUTH LA SALLE STREET, SUITE 1600, CHICAGO, IL, 60603-3406

NUMBER OF CLAIMS: 40

EXEMPLARY CLAIM: 1

LINE COUNT: 4514

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to new pyridyl alkane acid amides according to general formula (I) as well as methods for their production, medicaments containing these compounds as well as their medical use, especially in the treatment of tumors or for immunosuppression.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2003:232771 USPATFULL

TITLE: Pyridyl alkane acid amides as cytostatics and immunosupressives

INVENTOR(S): Biedermann, Elfi, Vaterstetten, GERMANY, FEDERAL REPUBLIC OF
Hasmann, Max, Neuried, GERMANY, FEDERAL REPUBLIC OF
Loser, Roland, Feldafing, GERMANY, FEDERAL REPUBLIC OF
Rattel, Benno, Munich, GERMANY, FEDERAL REPUBLIC OF
Reiter, Friedemann, Putzbrunn, GERMANY, FEDERAL REPUBLIC OF
Schein, Barbara, Neufahrn, GERMANY, FEDERAL REPUBLIC OF
Seibel, Klaus, Grafelfing, GERMANY, FEDERAL REPUBLIC OF
Vogt, Klaus, Munich, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Klinge Pharma GmbH (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003162972	A1	20030828
	US 7241745	B2	20070710
APPLICATION INFO.:	US 2002-213952	A1	20020805 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-242540, filed on 18 Feb 1999, ABANDONED A 371 of International Ser. No. WO 1997-EP3245, filed on 20 Jun 1997, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19624659	19960620

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FITCH EVEN TABIN AND FLANNERY, 120 SOUTH LA SALLE STREET, SUITE 1600, CHICAGO, IL, 60603-3406
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
LINE COUNT: 4806
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to new pyridyl alkane acid amides according to general formula (I) as well as methods for their production, medicaments containing these compounds as well as their medical use, especially in the treatment of tumors or for immunosuppression. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2002:288098 USPATFULL
TITLE: Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy
INVENTOR(S): Biedermann, Elfi, Vaterstetten, GERMANY, FEDERAL REPUBLIC OF
Eisenburger, Rolf, Kirchseeon, GERMANY, FEDERAL REPUBLIC OF
Hasmann, Max, Neuried, GERMANY, FEDERAL REPUBLIC OF
Loser, Roland, Feldafing, GERMANY, FEDERAL REPUBLIC OF
Rattel, Benno, Munich, GERMANY, FEDERAL REPUBLIC OF
Reiter, Friedemann, Putzbrunn, GERMANY, FEDERAL REPUBLIC OF
Schein, Barbara, Neufahrn, GERMANY, FEDERAL REPUBLIC OF
Schemainda, Isabel, Munich, GERMANY, FEDERAL REPUBLIC OF
Schulz, Michael, Aschheim, GERMANY, FEDERAL REPUBLIC OF
Seibel, Klaus, Grafelfing, GERMANY, FEDERAL REPUBLIC OF
Vogt, Klaus, Munich, GERMANY, FEDERAL REPUBLIC OF
Wosikowski, Katja, Poing, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Klinge Pharma GmbH (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002160968	A1	20021031
	US 6506572	B2	20030114
APPLICATION INFO.:	US 2001-935772	A1	20010823 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2000-EP1628, filed on 28 Feb 2000, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1999-103814	19990226

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FITCH EVEN TABIN AND FLANNERY, 120 SOUTH LA SALLE STREET, SUITE 1600, CHICAGO, IL, 60603-3406

NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 28 Drawing Page(s)
LINE COUNT: 3127
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB New biologically active compounds are described which inhibit the cellular formation of niacinamide mononucleotide, and essential intermediate of the NAD(P) biosynthesis in the cell. These compounds can represent the active ingredient of a pharmaceutical composition for the treatment of cancers, leukaemias or for immunosuppression. Furthermore, screening methods are described as a tool for detecting the above active compounds, and for examination of a given cell type for its dependency on niacinamide as a precursor for NAD synthesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2002:239033 USPATFULL
TITLE: Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
INVENTOR(S): Biedermann, Elfi, Vaterstetten, GERMANY, FEDERAL REPUBLIC OF
Hasmann, Max, Neuried, GERMANY, FEDERAL REPUBLIC OF
Loser, Roland, Feldafing, GERMANY, FEDERAL REPUBLIC OF
Rattel, Benno, Munich, GERMANY, FEDERAL REPUBLIC OF
Reiter, Friedemann, Putzbrunn, GERMANY, FEDERAL REPUBLIC OF
Schein, Barbara, Neufahrn, GERMANY, FEDERAL REPUBLIC OF
Seibel, Klaus, Grafelfing, GERMANY, FEDERAL REPUBLIC OF
Vogt, Klaus, Munich, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Klinge Pharma GmbH, Munich, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6451816	B1	20020917
APPLICATION INFO.:	US 1998-216482		19981218 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1997-EP3244, filed on 20 Jun 1997
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Rotman, Alan L.
ASSISTANT EXAMINER: Desai, Rita
LEGAL REPRESENTATIVE: Fitch, Even, Tabin, & Flannery
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 4285
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the use of pharmacologically valuable pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides according to general formula (I) in the treatment of tumors or for immunosuppression. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 16 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2002:224728 USPATFULL
TITLE: Pyridyl alkane acid amides as cytostatics and immunosuppressives
INVENTOR(S): Biedermann, Elfi, Vaterstetten, GERMANY, FEDERAL REPUBLIC OF
Hasmann, Max, Neuried, GERMANY, FEDERAL REPUBLIC OF
Loser, Roland, Feldafing, GERMANY, FEDERAL REPUBLIC OF

Rattel, Benno, Munich, GERMANY, FEDERAL REPUBLIC OF
Reiter, Friedemann, Putzbrunn, GERMANY, FEDERAL REPUBLIC OF
Schein, Barbara, Neufahrn, GERMANY, FEDERAL REPUBLIC OF
Seibel, Klaus, Gra felfing, GERMANY, FEDERAL REPUBLIC OF
Vogt, Klaus, Munich, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Klinge Pharma GmbH, Munich, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6444823	B1	20020903
APPLICATION INFO.:	US 1998-216075		19981218 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1997-EP3243, filed on 20 Jun 1997

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19624704	19960620

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Rotman, Alan L.
ASSISTANT EXAMINER: Desai, Rita
LEGAL REPRESENTATIVE: Fitch, Even, Tabin & Flannery
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3772
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to new pyridyl alkane acid amides according to general formula (I) as well as methods for their production, medicaments containing these compounds as well as their medical use, especially in the treatment of tumors or for immunosuppression. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 17 OF 17 USPATFULL on STN
ACCESSION NUMBER: 92:101011 USPATFULL
TITLE: Piperidinoalkyl derivatives of carboxylic acid amides
INVENTOR(S): Goto, Giichi, Osaka, Japan
Nagaoka, Akinobu, Hyogo, Japan
PATENT ASSIGNEE(S): Takeda Chemical Industries, Inc., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5169856		19921208
APPLICATION INFO.:	US 1989-306579		19890206 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1988-32339	19880215
	JP 1988-114169	19880511

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Raymond, Richard L.
ASSISTANT EXAMINER: O'Sullivan, Peter G.
LEGAL REPRESENTATIVE: Wegner, Cantor, Mueller & Player
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 999
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to unsaturated carboxylic acid amide derivatives of the formula ##STR1## wherein ring A stands for an

optionally substituted aromatic ring; R.sup.1 stands for a hydrogen atom or an optionally substituted hydrocarbon residue or forms an optionally substituted carbocyclic ring with the adjacent group --CH.dbd.C-- together with two carbon atoms constituting the ring A; R.sup.2 stands for a hydrogen atom, an optionally substituted hydrocarbon residue or an optionally substituted acyl group; R.sup.3 stands for an optionally substituted hydrocarbon residue; and n denotes an integer ranging from 2 to 6, and salts thereof, as well as the production thereof.

The compounds of the present invention act on the central nervous system of mammals and has a strong anti-cholinesterase activity, which can be used for the prophylaxis and therapy of, for example, senile dementia, Alzheimer's diseases, Huntington's chorea, et., and are useful as medicines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:17:55 ON 21 AUG 2007)

FILE 'REGISTRY' ENTERED AT 12:18:06 ON 21 AUG 2007
L1 STRUCTURE UPLOADED
L2 180 S L1 FULL

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 12:18:58 ON 21 AUG 2007
L3 47 S L2
L4 12 S L3 NOT PY>2003
L5 1 S L3 AND "VITAMIN PP"
L6 18 S L3 AND "NICOTINAMIDE"

FILE 'USPATFULL' ENTERED AT 12:25:19 ON 21 AUG 2007
L7 17 S L2

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	47.89	320.44
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-12.48

STN INTERNATIONAL LOGOFF AT 12:29:22 ON 21 AUG 2007